Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The neuromuscular junction (NMJ) is a specialized synapse where a motor neuron communicates with a skeletal muscle fiber to control muscle contraction. It involves the release of acetylcholine (ACh) from the presynaptic terminal, binding to nicotinic acetylcholine receptors (nAChRs) on the postsynaptic membrane, and subsequent muscle fiber depolarization leading to contraction. Acetylcholinesterase (AChE) rapidly degrades ACh, terminating the signal. The NMJ is crucial for voluntary movement and is the target of various diseases and drugs.
Modulation of neuromuscular signaling, affecting acetylcholine levels or receptor activity.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuromuscular Junction Transmission (NMJ).